A new clinical research study, The CONVERT study, is evaluating an investigational medication—Liposomal Amikacin for Inhalation (LAI)—in adult patients with Nontuberculous Mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC).
Insmed Incorporated are looking for patients, aged 18 years and older, with NTM lung disease caused by MAC, who have not experienced success with previous treatment. You may be eligible for participation in this clinical research study if you have an NTM lung disease caused by MAC, and continue to test positive for MAC while taking your oral antibiotics.
If you would like to participate, and you are eligible, you will be randomized to one of two groups: one group will receive LAI in addition to oral antibiotics, and one group will receive only the oral antibiotics. Participants will be required to attend study visits approximately once a month for up to 31 months.
By participating in the CONVERT study, you contribute to the understanding of chronic lung infections due to MAC, how the body processes LAI through pharmacokinetics, and whether successful treatment with LAI can help improve quality of life.
If you or someone you love has this condition, or suspects it, you can find out more about this new research study, find study locations near you, or request to be contacted by a study site, visit www.ConvertResearchStudy.com or call 866-825-3418.